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Sodium Benzoate
Through the last decade of  scientific re-
search, there has been a gradual focus shift 
from monoamines as the main therapeutic 
target of  psychopharmacology. Nowadays 
it’s the glutamate system, especially its recep-
tors, that has become increasingly interesting 
in terms of  possible treatment modalities. 
In fact, altered functioning of  N-methyl-D-
aspartate (NMDA) subtype of  glutamate re-
ceptors in the brain has an important role in 
the pathophysiology of  schizophrenia. We 
must stress that NMDA receptors are prov-
en to have a critical role in synaptic plastic-
ity, neurocognition and neurotoxicity. Based 
on these findings, improved signalisation via 
NMDA receptors in the brain is considered 
to be a new therapeutic approach in alleviat-
ing symptoms of  schizophrenia [1]. One of  
the methods for improving NMDA receptors 
function is increasing the level of  D-amino 
acids by reducing their metabolism. This can 
be achieved with an D-amino oxidase in-
hibitor. D-amino oxidase is a flavoenzyme 
which breaks down D-amino acids by oxi-
dative deamination. Recent genetic research 
has identified a mutation on chromosome 
13 in patients with schizophrenia that codes 
two proteins (G30 and G72) associated with 
D-amino oxidase, with increased expression 
and activity in post-mortem brain samples 
of  patients with schizophrenia compared  to 
healthy population [2, 3]. D-serine, one of  the 
amino acids regulated with D-amino oxidase 
is a potent endogenous coagonist of  NMDA 
receptors and it has been proven that D-ami-
no oxidase inhibitors increase the concentra-
tion of  D-serine in the blood and brain [2]. 
As the first molecule from this group we 
present sodium benzoate (Benzoate - Syn-
euRx, Clozaben, NaBen, SND 51, SND-11, 
SND-12, SND-13, SND-14), which is cur-
rently in the clinical research phase as add-
on therapy in treatment of  schizophrenia 
in adults [4, 5]. Benzoic acid was discovered 
in the 16th Century by dry distillation of  
gum benzoin, first described by Nostrada-
mus. In nature it appears in free form and 
in the form of  benzoic acid esters in many 
plants and animals. It is also present in vari-
ous types of  food, including dairy products. 
Benzoic acid salts are known and safe food 
preservatives widely used in industry, es-
pecially in meat processing [6]. It has been 
clinically demonstrated that sodium benzoate 
improves a broad spectrum of  symptom do-
mains in schizophrenia and is clinically signif-
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icant for patients with chronically expressed 
symptomatology [4]. It is very promising to 
see that this molecule alleviates symptoms 
of  schizophrenia that had resisted therapy 
with antipsychotics. This indicates a poten-
tial effectiveness in therapy resistant cases. It 
is important to stress that sodium benzoate 
as an „NMDA enhancer” also acts on cog-
nitive symptoms of  schizophrenia, which is 
especially important as cognitive symptoms 
are considered to be the key problem and a 
significant predictor of  outcome in schizo-
phrenia [6]. Sodium benzoate (under protect-
ed name NaBen) has been named an „orphan 
drug“ by the American Food and Drugs Ad-
ministration (FDA) i. e. suitable for paediatric 
patients with schizophrenia and in cases of  
clozapine treatment refractory schizophre-
nia. The same agency considers this molecule 
as breakthrough therapy, thus attempting to 
encourage and speed up drug development 
for treatment of  schizophrenia in adults. A 
IIb/III phase of  a multicentric prospective 
double blind, placebo controlled research 
study on the safety and efficiency of  NaBen 
as additional therapy of  adult patients with 
schizophrenia, is currently being conducted. 
The time of  its market release is unknown. 
[6, 7]. The chemical structure of  sodium ben-
zoate is presented in figure 1.
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Figure 1. Chemical structure of  sodium benzoate
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